Cost-Minimization Analysis of Tolvaptan Treatment for ADPKD in Southern Spain. [PDF]
Kidney Int RepRoca Oporto FJ +5 more
europepmc +1 more source
Effectiveness of tolvaptan on renal replacement therapy in patients with autosomal dominant polycystic kidney disease: a retrospective cohort study from the TriNetX global collaborative network. [PDF]
Ren FailWu MJ, Chen CH, Tsai SF.
europepmc +1 more source
Evaluation of tolvaptan-associated hepatic disorder using different national pharmacovigilance databases. [PDF]
Sci RepUno T, Hosomi K, Yokoyama S.
europepmc +1 more source
Low-dose tolvaptan to control disease progression in Chinese patients with autosomal dominant polycystic kidney disease: a retrospective cohort study. [PDF]
Transl Androl UrolZhou L, Wei X, Wang B, Xu Q, Li W.
europepmc +1 more source
A Rare Coexisting Presentation of Autosomal Dominant Polycystic Kidney Disease With Rapid Deterioration of Renal Function and Neurofibromatosis Type 1. [PDF]
CureusNoishiki H +4 more
europepmc +1 more source
Beyond dyspnoea as an endpoint in acute heart failure trials [PDF]
, 2017 Gheorghiade, Mihai, Ruschitzka, Frank
core
Uncovering the molecular mechanisms of tonifying kidney and activating blood Decoction against myocardial fibrosis using network Pharmacology and experimental validation. [PDF]
Sci RepXu R +6 more
europepmc +1 more source
Prognostic Impact of Long-Term Sodium Zirconium Cyclosilicate-Integrated Medical Therapy in Patients with Systolic Heart Failure. [PDF]
J Clin MedHida Y, Imamura T, Kinugawa K.
europepmc +1 more source
Multisystemic impact of autosomal dominant polycystic kidney disease: A case report highlighting renal, hepatic, and neurological involvement. [PDF]
Radiol Case RepKhalil I +3 more
europepmc +1 more source